Sucampo Pharma (SCMP) Misses Q3 EPS by 1c; Boosts FY14 Earnings Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sucampo Pharmaceutical (SCMP) PT Lifted to $14 at Maxim Group on Robust Amitza Growth
November 6, 2014 3:15 PM ESTMaxim Group analyst Jason Kolbert reiterated a Buy rating and bumped his price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to $14.00 (from $10.00) following Q3 results noting double-digit growth for Amitza to end the quarter.
"Sucampo surprised with double-digit sequential growth for Amitiza at... More
